Skip to main content

Table 2 Groups of mediators to be measured using Luminex® bead-based multiplexing technology

From: Efficacy and safety of active negative pressure peritoneal therapy for reducing the systemic inflammatory response after damage control laparotomy (the Intra-peritoneal Vacuum Trial): study protocol for a randomized controlled trial

Bio-Plex Proâ„¢ Human Cytokine 21-plex Assay (Bio-Rad Laboratories)

Bio-Plex Proâ„¢ Human Cytokine 27-plex Assay (Bio-Rad Laboratories)

Bio-Plex Proâ„¢ Human Acute Phase 5- + 4-Plex Panel Complete (Bio-Rad Laboratories)

Bio-Plex Proâ„¢ Human Custom 8-Plex (Bio-Rad Laboratories)

IL-1α

IL-1β

Ferritin

IL-17F

IL-2Rα

IL-1ra

Fibrinogen

IL-21

IL-3

IL-2

Procalcitonin

IL-22

IL-12 (p40)

IL-4

Serum amyloid A

IL-23

IL-16

IL-5

tPA

IL-25

IL-18

IL-6

α2-macroglobulin

IL-31

CTACK (CCL27)

IL-7

CRP

IL-33

GRO-α (CXCL1)

IL-8

Haptoglobulin

sCD-40L

HGF

IL-9

Serum amyloid P

 

IFN-α2

IL-10

  

LIF

IL-12 (p70)

  

MCP-3 (CCL7)

IL-13

  

M-CSF

IL-15

  

MIF

IL-17

  

MIG (CXCL9)

Basic FGF

  

β-NGF

Eotaxin (CCL11)

  

SCF

G-CSF

  

SCGF-β

GM-CSF

  

SDF-1α

IFN-γ

  

TNF-β

IP-10 (CXCL10)

  

TRAIL

MCP-1 (CCL2)

  
 

MIP-1α (CCL3)

  
 

MIP-1β (CCL4)

  
 

PDGF-BB

  
 

RANTES (CCL5)

  
 

TNF-α

  
 

VEGF

  
  1. Basic FGF, Basic fibroblast growth factor; β-NGF, Beta-nerve growth factor; CCL2, Chemokine (C-C motif) ligand 2; CCL3, Chemokine (C-C motif) ligand 3; CCL4, Chemokine (C-C motif) ligand 4; CCL7, Chemokine (C-C motif) ligand 7; CCL11, Chemokine (C-C motif) ligand 11; CCL27, Chemokine (C-C motif) ligand 27; CRP, C-reactive protein; CTACK, Cutaneous T-cell-attracting chemokine; CXCL1, Chemokine (C-X-C motif) ligand 1; CXCL9, Chemokine (C-X-C motif) ligand 9; CXCL10, Chemokine (C-X-C motif) ligand 10; eotaxin, Eosinophil chemotactic protein; G-CSF, Granulocyte colony-stimulating factor; GM-CSF, Granulocyte macrophage colony-stimulating factor; GRO-α, Growth-related oncogene-alpha; HGF, Hepatocyte growth factor; IFN-α2, Interferon alpha-2; IFN-γ, Interferon-gamma; IL-1α, Interleukin-1-alpha; IL-1β, Interleukin-1-beta; IL-1ra, Interleukin-1 receptor antagonist; IL-2, Interleukin-2; IL-2Rα, Interleukin-2 receptor-alpha; IL-3, Interleulin-3; IL-4, Interleukin-4; IL-5, Interleukin-5; IL-6, Interleukin-6; IL-7, Interleukin-7; IL-8, Interleukin-8; IL-9, Interleukin-9; IL-10, Interleukin-10; IL-12 (p40), Interleukin-12 beta subunit; IL-12 (p70), Interleukin-12 (active heterodimer of IL-12 (p40) and IL-12 (p35)); IL-13, Interleukin-13; IL-15, Interleukin-15; IL-16, Interleukin-16; IL-17, Interleukin-17; IL-17F, Interleukin-17F; IL-18, Interleukin-18; IL-21, Interleukin-21; IL-22, Interleukin-22; IL-23, Interleukin-23; IL-25, Interleukin-25; IL-31, Interleukin-31; IL-33, Interleukin-33; IP-10, Interferon gamma-induced protein 10; LIF, Leukemia inhibitory factor; M-CSF, Macrophage colony-stimulating factor; MCP-1, Monocyte chemoattractant protein-1; MCP-3, Monocyte-specific chemokine 3; MIF, Macrophage migration inhibitory factor; MIG, Monokine induced by gamma interferon; MIP-1α, Macrophage inflammatory protein-1-alpha; MIP-1β, Macrophage inflammatory protein-1-beta; PDGF-BB, Platelet-derived growth factor-B homodimer; RANTES, Regulated and normal T cell expressed and secreted; sCD-40L, Soluble cluster of differentiation 40 ligand; SCF, Stem cell factor; SCGF-β, Stem cell growth factor-beta; SDF-1α, Stromal cell-derived factor-1; TNF-α, Tumor necrosis factor-alpha; TNF-β, Tumor necrosis factor-beta; tPA, Tissue plasminogen activator; TRAIL, Tumor necrosis factor-related apoptosis-inducing ligand; VEGF, Vascular endothelial growth factor.
Back to article page

Trials

ISSN: 1745-6215